We, the authors, wish to make the following corrections to our paper [1]:
The compound with the code name BAL27862 is Avanbulin, not Plinabulin.
This affects:
Table 1 (page 25) – the entry for Plinabulin should not have BAL27862 after it. This entry refers to Plinabulin (BPI-2358) in clinical trials. The structural features listed alongside this entry are incorrect (refer to 75, avanbulin). The structural features of Plinabulin include a piperazinedione structure.
The structure of Plinabulin not currently included in the text. The structure is shown below for reference:
Table 1 (page 25) – entry for Lisavanbulin should state “Lysine prodrug of Avanbulin (75)” in column 3 (structural features).
Page 26 – Section 5.6 refers to Avanbulin (BAL27862) (75).
The last line of Section 5.6 should be removed (“It is also known as plinabulin and is now in clinical trials.”) It should read: “It is also known as avanbulin.”
Page 32 – Section 6.2.2.
This paragraph refers to Beyond Spring’s compound, Plinabulin (provisional name BPI-2358, formerly NPI-2358). References to BAL27862 and 75 should be removed from this paragraph (first line).
Page 33 – Section 6.2.3.
The first line should read “... prodrug of BAL27862/avanbulin (75, Figure 11) ...” (i.e., plinabulin changed to avanbulin).
The authors would like to apologize for any inconvenience caused to the readers by these changes.
Acknowledgments
We thank Basilea Pharmaceutica International Ltd. for pointing out the error.
Reference
- 1.McLoughlin E.C., O’Boyle N.M. Colchicine-Binding Site Inhibitors from Chemistry to Clinic: A Review. Pharmaceuticals. 2020;13:8. doi: 10.3390/ph13010008. [DOI] [PMC free article] [PubMed] [Google Scholar]